Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping nerves without a scalpel: can radiofrequency quiet chronic pain?

NCT ID NCT07831447

NEW Symptom relief Sponsor: Hypersound Medical Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are testing whether a noninvasive device called Hypersound can reduce chronic neuropathic or radicular pain in adults. The system uses external antennas to deliver radiofrequency energy to peripheral nerves without implants or needles. About 71 participants receive ten 15-minute sessions over five weeks, with two out of three assigned to active treatment and the rest to a sham. The main question is how many people report at least a 50% drop in average pain intensity 90 days after starting treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a noninvasive peripheral nerve stimulation device that delivers radiofrequency energy through external antennas
What this could lead to
If it works, this could offer a drug-free, needle-free way to turn down chronic nerve pain without surgery or implanted hardware.
What could go wrong
The trial is small and early, and sham-controlled pain studies often fail because placebo responses are strong. Radiofrequency energy aimed at nerves can also cause skin irritation or temporary discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 71 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2027

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Clinically confirmed chronic neuropathic or radicular pain of at least three months' duration. * An identifiable anatomical treatment target. * Baseline pain meeting the minimum intensity threshold specified in the protocol. * Stable pain-treatment regimen as defined in the protocol. * Able to provide informed consent and to complete patient-reported assessments. * Willing to complete the treatment course and follow-up visits. Exclusion Criteria: * Unstable medical or neurological disease. * Another dominant source of pain that would interfere with evaluation of the target pain condition. * Inability to reliably report outcomes. * Contraindications to the investigational device as specified in the protocol. * Major recent changes in pain treatment, as defined in the protocol. * Participation in another intervention likely to materially affect study outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic neuropathic pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuropathy, painful radiculopathy sciatica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic neuropathic pain Peripheral neuropathic pain Radiculopathy Sciatica

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for Pain and Supportive Care

    Phoenix, Arizona, 85028, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.